What the FDA labels say about taking them together
Ethinyl estradiol/norgestimate and ritonavir
Ethinyl estradiol/norgestimate's FDA label of February 6, 2026 names ritonavir in its contraindications section; the ritonavir label PlainMeds reads does not name ethinyl estradiol/norgestimate. The ethinyl estradiol/norgestimate label: “Human immunodeficiency virus (HIV)/Hepatitis C virus (HCV) protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and HIV/AIDS medications containing strong inhibitors or inducers of CYP3A Significant …”
Check it at the source: the ethinyl estradiol/norgestimate FDA label on DailyMed (effective February 6, 2026, Glenmark Pharmaceuticals Inc., USA); the ritonavir FDA label on DailyMed (effective July 23, 2026, AbbVie Inc.).
What does the ethinyl estradiol/norgestimate label say about ritonavir?
Ethinyl estradiol/norgestimate label, contraindicationsUse of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations [see Warnings and Precautions( 5.3 )]
Ethinyl estradiol/norgestimate label, drug interactionsHuman immunodeficiency virus (HIV)/Hepatitis C virus (HCV) protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and HIV/AIDS medications containing strong inhibitors or inducers of CYP3A Significant changes (increase or decrease) in the plasma concentrations of estrogen and/or progestin have been noted in some cases of co-administration with HIV protease inhibitors (decrease [e.g., nelfinavir, ritonavir, darunavir/ritonavir, (fos)amprenavir/ritonavir, lopinavir/ritonavir, and tipranavir/ritonavir] or increase [e.g., indinavir and atazanavir/ritonavir])/HCV protease inhibitors (decrease [e.g., boceprevir and telaprevir]) or with non-nucleoside reverse transcriptase …
Ethinyl estradiol/norgestimate label, warnings and precautionsElevations with Concomitant Hepatitis C Treatment During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications, such as COCs.
Source: FDA drug label (Norgestimate and Ethinyl Estradiol), Glenmark Pharmaceuticals Inc., USA, effective February 6, 2026 (SPL set 8b247e46-203e-4f5b-b5a7-cbd57341c735), via openFDA; the full label on DailyMed
What does the ritonavir label say about ethinyl estradiol/norgestimate?
Ritonavir's label (effective July 23, 2026) does not name ethinyl estradiol/norgestimate in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Norvir), AbbVie Inc., effective July 23, 2026 (SPL set 2849298e-de6e-47bb-8194-56e075b33fc3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ethinyl estradiol/norgestimate | Ritonavir | |
|---|---|---|
| Labeled for | Acne, Birth control | HIV |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.115 per tablet 0.25-0.035 mg tablet | $0.607 per tablet 100 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once